Abbott Laboratories expected to increase Q2 2025 adjusted EPS, positive.

From Yahoo Finance.: 2025-06-30 06:22:00

Abbott Laboratories, a global healthcare company, is set to announce its fiscal Q2 2025 earnings results on July 17. Analysts expect an adjusted EPS of $1.25, up 9.7% from the previous year. For fiscal 2025, ABT is projected to report adjusted EPS of $5.16, increasing to $5.67 in fiscal 2026.

Shares of ABT have surged 28.4% over the past year, outperforming the S&P 500 and Health Care Select Sector SPDR Fund. Despite weaker Q1 2025 revenue, Abbott’s stock rose 2.8% and reaffirmed its full-year profit forecast. The company also announced $500 million in new investments in manufacturing and R&D.

Abbott’s stronger-than-expected Q1 adjusted EPS of $1.09, along with ongoing global production of high-demand products, boosted investor sentiment. Analysts have a bullish consensus rating on ABT stock, with a majority recommending a “Strong Buy.” The average price target for ABT is $143.65, indicating a potential upside of 6.9%.

Read more: What to Expect From Abbott Laboratories’ Q2 2025 Earnings Report